Scientists hunt for clues to rare CAR-T side effects in myeloma

NCT ID NCT07665307

Recruiting now Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. The goal is to better understand these side effects and improve how doctors monitor and treat them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ciltacabtagene autoleucel (cilta-cel)
What this could lead to: If successful, this study could point toward better ways to predict, monitor, and manage rare but serious side effects of CAR-T therapy, making treatment safer for future patients.
What could go wrong: This is a small, early observational study (30 participants) that does not test a new treatment. It may not find clear biomarkers, and results may not apply to all patients or CAR-T products.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm toxic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Mount Sinai
RECRUITING

New York, New York, 10029, United States
UCSF Medical Center
RECRUITING

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.